Influenza A/B-Q Real-Time PCR Kit

Product Overview

Influenza remains one of the most pervasive respiratory infections worldwide, responsible for 3 to 5 million severe cases and up to 650,000 deaths annually according to the WHO. Caused primarily by Influenza A and B viruses, it spreads rapidly through respiratory droplets and can escalate to life-threatening complications in young children, the elderly, and immunocompromised individuals. With multiple co-circulating subtypes including H1N1 and H3N2, accurate subtype-level identification is essential for effective treatment and outbreak control.

The Influenza A/B-Q Real-Time PCR Kit from Genes2Me delivers definitive subtype-level detection in a single workflow. Using a two-tube multiplex RT-PCR design, it simultaneously identifies Influenza A, Influenza B, H1N1, and H3N2 directly from nasopharyngeal and oropharyngeal swabs, with no ambiguity and no compromise on accuracy.

Targets:
Influenza A, Influenza B, H1N1, H3N2
Technology:
TaqMan based Multiplex Real-Time PCR
Detection:
Qualitative (Detected / Not Detected)
Sample Type:
Nasopharyngeal & Oropharyngeal Swabs
Certification:
CE-IVD
Influenza-rtpcr

Genes2Me is a CE Marked molecular diagnostics company trusted by clinical laboratories across global markets. The Influenza A/B-Q Kit meets European conformity standards for in vitro diagnostic devices, validated to international benchmarks for accuracy, reliability, and safety.

How the Assay Works

The Influenza A/B-Q kit uses a two-tube multiplex Real-Time Reverse Transcription PCR design. Tube 1 targets the Influenza A matrix protein 2, Influenza B nuclear export protein (NEP), and H1N1 hemagglutinin gene. Tube 2 specifically detects the H3 and N2 subtypes. Each viral target is monitored through a distinct fluorescent channel: FAM, HEX, and Texas Red, with RNaseP serving as an internal control on the Cy5 channel to validate extraction and amplification in every run.

Why Multiplex Testing Matters

Influenza A and B co-circulate each season alongside distinct subtypes such as H1N1 and H3N2, each requiring different clinical management strategies. Multiplex testing enables simultaneous subtype-level detection with built-in controls, reducing the risk of false negatives and ensuring accurate, timely identification. This is critical not only for individual patient management but also for public health surveillance and outbreak response.

Sample Type & Reporting Output

Sample Type:
Nasopharyngeal and oropharyngeal swab samples
Reporting Output:
Qualitative detection of Influenza A, B, H1N1, H3N2 (Detected / Not Detected)
Targets Detected:
Influenza A, Influenza B, H1N1, H3N2

Key Features & Benefits

Two-tube multiplex RT-PCR design

Tube 1 detects Influenza A, Influenza B, and H1N1; Tube 2 targets H3 and N2 subtypes, enabling comprehensive subtype differentiation in a single workflow.

Four-channel fluorescent detection

FAM, HEX, and Texas Red channels monitor individual viral targets, with RNaseP internal control on Cy5 ensuring robust extraction and amplification validation.

High sensitivity detection

Detects as few as 41 copies/mL of viral RNA, enabling confident identification even in early-stage or low-titre infections.

100% analytical and clinical specificity

Rigorous design ensures precise differentiation of influenza subtypes with no cross-reactivity, delivering consistent and trustworthy results.

Compatible with multiple leading PCR platforms

Validated on RapiCycler 96, Bio-Rad CFX96, QuantStudio 5, and LightCycler 480.

Rapid turnaround with streamlined workflow

User-friendly setup and clear amplification protocols deliver results within hours, supporting timely clinical decision-making.

Applications

  • Clinical & Hospital Laboratories: Enables rapid differential diagnosis of influenza A, B, H1N1, and H3N2, supporting targeted antiviral treatment decisions and effective infection control.
  • Paediatric & Neonatal Care: Early identification of influenza subtypes in young children and infants, where complications such as pneumonia and febrile seizures can escalate rapidly.
  • Outbreak Surveillance: Supports real-time monitoring and containment of seasonal influenza outbreaks in hospitals, schools, care homes, and community settings.
  • Immunocompromised Patients: Precise subtype identification for transplant recipients, oncology patients, and those on immunosuppressive therapy, enabling targeted management of high-risk cases.
  • Travel & Occupational Health: Reliable subtype-level screening in international travel clinics, airports, and occupational health programmes where influenza transmission risk is elevated.

Analytical Performance

  • 100% analytical sensitivity and specificity
  • 100% clinical specificity across all four targets
  • Limit of detection: as few as 41 copies/mL of viral RNA
  • No cross-reactivity with common respiratory pathogens including RSV, SARS-CoV-2, and Bordetella pertussis

Ordering Information

Commercial Name Old Cat No. New Cat No. Pack Size
Influenza A/B-Q Real-Time PCR Kit G2M706021R 50 Tests

Product Enquiry Form

Other Products

Rapi-Q Series
Rapi-Q

Rapid and Compact Point-of-care RT-PCR Testing Solution.

Rapi-X96
RAPiCycler-96

Real time PCR system to process 96 samples.
TRapi-X96
Rapi-X16

Compact Nucleic Acid Extraction System Ideal for Point-of-Care Testing

Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.

© 2025 Genes2me. All rights reserved.